Marcel Spaargaren

Has grant

Dean

Country flagNetherlands

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Marcel Spaargaren is the Dean at the Oncology Graduate School Amsterdam (OOA) in the Netherlands. His research focuses on the molecular mechanisms underlying B-cell malignancies, particularly in relation to lymphoma and multiple myeloma. Recent publications include studies on CXCL12γ and its effects on CXCR4 activation, as well as the role of the MYD88 L265P mutation in lymphoma aggression. He is also involved in exploring innovative combination therapies to enhance treatment efficacy in B-cell cancers.

Recent Grants

Grant: Close

Targeting bone marrow retention to provoke homelessness of the tumor cells as a strategy to cure Multiple Myeloma

Open Date: 2018-01-01

Close Date: 2021-12-31

Grant: Close

The role of stromal heparan sulfate proteoglycans and the novel chemokine CXCL12 y in the bone marrow niche of Multiple Myeloma

Open Date: 2012-12-01

Close Date: 2016-12-01

Grant: Close

The role of the forkhead transcription factor FOXP1 in B-cell non-Hodgkin lymphoma

Open Date: 2007-09-01

Close Date: 2011-09-01

Articles (11)

Year:

2025

Year:

2023

Metabolic alterations are important cancer-associated features that allow cancer cell transformation and survival under stress conditions. Multiple myeloma (MM) plasma cells show increased glycolysis and oxidative phosphorylation (OXPHOS), which are characteristics associated with recurrent genetic aberrations that drive the proliferation and survival of MM cells. The protein kinase B/AKT acts as a central node in cellular metabolism and is constitutively active in MM cells. Despite the known role of AKT in modulating cellular metabolism, little is known about the downstream factors of AKT that control the metabolic adaptability of MM cells. Here, we demonstrate that negative regulation of the forkhead box O (FOXO) transcription factors (TFs) by AKT is crucial to prevent the metabolic shutdown in MM cells, thus contributing to their metabolic adaptability. Our results demonstrate that the expression of several key metabolic genes involved in glycolysis, the tricarboxylic acid (TCA) cycle, and OXPHOS are repressed by FOXO TFs. Moreover, the FOXO-dependent repression of glycolysis- and TCA-associated genes correlates with a favorable prognosis in a large cohort of patients with MM. Our data suggest that repression of FOXO by AKT is essential to sustain glycolysis and the TCA cycle activity in MM cells and, as such, predicts patient survival.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Roderick Beijersbergen

Professor and head division

The Netherlands Cancer Institute

NETHERLANDS
View details

Cody Ashby

Assistant Professor

University of Arkansas for Medical Sciences

UNITED STATES
View details

Jeroen E. J. Guikema

Amsterdam University Medical Centers

NETHERLANDS
View details

Jaap D van Buul

University of Amsterdam

NETHERLANDS
View details

Eric Eldering

groupleader/professor

Academic Medical Center

NETHERLANDS
View details

Cristina Muñoz-Pinedo

Institut d'Investigacions Biomèdiques de Barcelona

SPAIN
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.